Josep Prous | BiotechTV

top of page

BIO-Europe 2025: Barcelona based Connecta Therapeutics is moving its neuroplasticity modulator for fragile X syndrome into a phase 2a study after completing first in human studies late last year

CEO Jordi Fàbrega and CSO Josep Prous discusses the asset, CTH120, which is a NCE and proprietary to Connecta. Coverage brought to you by

Company News

21 hours ago

Follow BiotechTV

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

Evaluate is a trusted provider of forecasting and commercial intelligence to the pharmaceutical industry. With a combination of gold standard data sources and deep pharma expertise, Evaluate helps clients make the right portfolio decisions to drive growth.

Evaluate's solutions provide a complete, dynamic view of development risk and commercial return across the full clinical lifecycle, underpinned by consensus forecasts to 2032, pipelines, deals and more. A consulting and analytics team is on always hand to help clients address unique clinical and commercial challenges.

Learn more about Evaluate

bottom of page

BIO-Europe 2025: Barcelona based Connecta Therapeutics is moving its neuroplasticity modulator for fragile X syndrome into a phase 2a study after completing first in human studies late last year

Follow BiotechTV

Sponsors

Sponsor Spotlight